Top

Published in:

Open Access 01-12-2021 | Migraine | Research article

Impact of the COVID-19 pandemic on migraine in Japan: a multicentre cross-sectional study

Authors: Keisuke Suzuki, Takao Takeshima, Hisaka Igarashi, Noboru Imai, Daisuke Danno, Toshimasa Yamamoto, Eiichiro Nagata, Yasuo Haruyama, Takashi Mitsufuji, Shiho Suzuki, Yasuo Ito, Mamoru Shibata, Hisanori Kowa, Shoji Kikui, Tomohiko Shiina, Madoka Okamura, Muneto Tatsumoto, Koichi Hirata

Published in: The Journal of Headache and Pain | Issue 1/2021

Abstract

Objectives

To assess the impacts of social situation changes due to the coronavirus disease 2019 (COVID-19) pandemic on headache-related disability and other symptoms in patients with migraine in Japan.

Methods

We conducted a multicentre, cross-sectional study including 659 outpatients with migraine diagnosed by headache specialists. The participants were asked about the impacts of the first wave of the COVID-19 pandemic on headache-related disability, headache days, headache intensity, stress, physical activity, hospital access and their work and home lives. For headache-related disability, the total Migraine Disability Assessment (MIDAS) score and part A and B scores were analysed. Multivariate stepwise linear regression analysis was performed to identify the clinical predictors of changes in the total MIDAS score before and during the COVID-19 pandemic. Logistic regression analysis was performed to determine the factors related to new-onset headache during the COVID-19 pandemic.

Results

Finally, 606 migraine patients (73 M/533 F; age, 45.2 ± 12.0 years) were included in the study, excluding those with incomplete data. Increased stress, substantial concern about COVID-19 and negative impacts of the first wave of the COVID-19 pandemic on daily life were reported in 56.8 %, 55.1 and 45.0 % of the participants, respectively. The total MIDAS and A and B scores did not significantly change after the first wave of the COVID-19 pandemic. New-onset headache, which was observed in 95 patients (15.7 %), was associated with younger age and worsened mood and sleep in the logistic regression analysis. The multivariate stepwise linear regression analysis of changes in the total MIDAS score before and during the first wave of COVID-19 pandemic identified worsened sleep, increased acute medication use, increased stress, medication shortages, comorbidities, the absence of an aura and new-onset headache were determinants of an increased total MIDAS score during the first wave of the COVID-19 pandemic.

Conclusions

In this multicentre study, clinical factors relevant to headache-related disability, such as new-onset headache, stress and sleep disturbances, were identified, highlighting the importance of symptom management in migraine patients during the first wave of the COVID-19 pandemic.

Available only for authorised users

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus I, Research T (2020) A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 382 (8):727–733. https://doi.org/10.1056/NEJMoa2001017

Ministry of Health, Labour and Welfare J. Characteristics of new coronavirus infections ascertained at present (As of March 28). 2020. Retrived from https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/newpage_00032.html.

Li Y, Qin Q, Sun Q, Sanford LD, Vgontzas AN, Tang X (2020) Insomnia and psychological reactions during the COVID-19 outbreak in China. J Clin Sleep Med 16(8):1417–1418. https://doi.org/10.5664/jcsm.8524CrossRefPubMed

Ozamiz-Etxebarria N, Dosil-Santamaria M, Picaza-Gorrochategui M, Idoiaga-Mondragon N (2020) Stress, anxiety, and depression levels in the initial stage of the COVID-19 outbreak in a population sample in the northern Spain. Cad Saude Publica 36(4):e00054020. https://doi.org/10.1590/0102-311X00054020CrossRefPubMed

Kristoffersen ES, Faiz KW, Sandset EC, Storstein AM, Stefansen S, Winsvold BS, Hansen JM (2020) Hospital-based headache care during the Covid-19 pandemic in Denmark and Norway. J Headache Pain 21(1):128. https://doi.org/10.1186/s10194-020-01195-2CrossRefPubMedPubMedCentral

Szperka CL, Ailani J, Barmherzig R, Klein BC, Minen MT, Halker Singh RB, Shapiro RE (2020) Migraine Care in the Era of COVID-19: Clinical Pearls and Plea to Insurers. Headache 60(5):833–842. https://doi.org/10.1111/head.13810CrossRefPubMedPubMedCentral

Grazzi L, Rizzoli P (2020) The Adaptation of Management of Chronic Migraine Patients With Medication Overuse to the Suspension of Treatment Protocols During the COVID-19 Pandemic: Lessons From a Tertiary Headache Center in Milan, Italy. Headache 60(7):1463–1464. https://doi.org/10.1111/head.13825CrossRefPubMed

Wells RE, Strauss LD (2020) The Value of Headache-Specific Recommendations During COVID-19. Headache 60(5):820–823. https://doi.org/10.1111/head.13821CrossRefPubMedPubMedCentral

Marmura MJ (2018) Triggers, Protectors, and Predictors in Episodic Migraine. Curr Pain Headache Rep 22(12):81. https://doi.org/10.1007/s11916-018-0734-0CrossRefPubMed

10.

Spierings EL, Donoghue S, Mian A, Wober C (2014) Sufficiency and necessity in migraine: how do we figure out if triggers are absolute or partial and, if partial, additive or potentiating? Curr Pain Headache Rep 18(10):455. https://doi.org/10.1007/s11916-014-0455-yCrossRefPubMed

11.

Minen MT, Begasse De Dhaem O, Van KroonDiest A, Powers S, Schwedt TJ, Lipton R, Silbersweig D (2016) Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry 87(7):741–749. https://doi.org/10.1136/jnnp-2015-312233CrossRefPubMed

12.

Smitherman TA, Kolivas ED (2013) Trauma exposure versus posttraumatic stress disorder: relative associations with migraine. Headache 53(5):775–786. https://doi.org/10.1111/head.12063CrossRefPubMed

13.

Arcaya MC, Lowe SR, Asad AL, Subramanian SV, Waters MC, Rhodes J (2017) Association of posttraumatic stress disorder symptoms with migraine and headache after a natural disaster. Health Psychol 36(5):411–418. https://doi.org/10.1037/hea0000433CrossRefPubMed

14.

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition (2018) Cephalalgia 38;(1):1-211. https://doi.org/10.1177/0333102417738202

15.

Suzuki K, Miyamoto T, Miyamoto M, Suzuki S, Watanabe Y, Takashima R, Hirata K (2013) Dream-enacting behaviour is associated with impaired sleep and severe headache-related disability in migraine patients. Cephalalgia 33(10):868–878. https://doi.org/10.1177/0333102413477742CrossRefPubMed

16.

Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39(2):175–191. https://doi.org/10.3758/bf03193146CrossRefPubMed

17.

Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN, Sawyer J (1999) An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 53(5):988–994. https://doi.org/10.1212/wnl.53.5.988CrossRefPubMed

18.

Guy W (2000) Clinical global impressions (CGI) scale, modified. In: Rush J (ed) Handbook of psychiatric measures, 1st edn. American Psychiatric Association, Washington

19.

Kuo WY, Huang CC, Weng SF, Lin HJ, Su SB, Wang JJ, Guo HR, Hsu CC (2015) Higher migraine risk in healthcare professionals than in general population: a nationwide population-based cohort study in Taiwan. J Headache Pain 16:102. https://doi.org/10.1186/s10194-015-0585-6CrossRefPubMedPubMedCentral

20.

Al-Hashel JY, Ismail II (2020) Impact of coronavirus disease 2019 (COVID-19) pandemic on patients with migraine: a web-based survey study. J Headache Pain 21(1):115. https://doi.org/10.1186/s10194-020-01183-6CrossRefPubMedPubMedCentral

21.

Delussi M, Gentile E, Coppola G, Prudenzano AMP, Rainero I, Sances G, Abagnale C, Caponnetto V, De Cesaris F, Frattale I, Guaschino E, Marcinno A, Ornello R, Pistoia F, Putorti A, Roca ME, Roveta F, Lupi C, Trojano M, Pierelli F, Geppetti P, Sacco S, de Tommaso M (2020) Investigating the Effects of COVID-19 Quarantine in Migraine: An Observational Cross-Sectional Study From the Italian National Headache Registry (RICe). Front Neurol 11:597881. https://doi.org/10.3389/fneur.2020.597881CrossRefPubMedPubMedCentral

22.

Verhagen IE, van Casteren DS, Lentsch SV, Terwindt GM (2021) Effect of lockdown during COVID-19 on migraine: A longitudinal cohort study. Cephalalgia:333102420981739. https://doi.org/10.1177/0333102420981739

23.

Ma M, Fang J, Li C, Bao J, Zhang Y, Chen N, Guo J, He L (2020) The status and high risk factors of severe psychological distress in migraine patients during nCOV-2019 outbreak in Southwest China: a cross-sectional study. J Headache Pain 21(1):100. https://doi.org/10.1186/s10194-020-01168-5CrossRefPubMedPubMedCentral

24.

Holsteen KK, Hittle M, Barad M, Nelson LM (2020) Development and Internal Validation of a Multivariable Prediction Model for Individual Episodic Migraine Attacks Based on Daily Trigger Exposures. Headache 60(10):2364–2379. https://doi.org/10.1111/head.13960CrossRefPubMed

25.

Kovacs LN, Baksa D, Dobos D, Eszlari N, Gecse K, Kocsel N, Juhasz G, Kokonyei G (2021) Perceived stress in the time of COVID-19: the association with brooding and COVID-related rumination in adults with and without migraine. BMC Psychol 9(1):68. https://doi.org/10.1186/s40359-021-00549-yCrossRefPubMedPubMedCentral

26.

Moon HJ, Seo JG, Park SP (2017) Perceived stress in patients with migraine: a case-control study. J Headache Pain 18(1):73. https://doi.org/10.1186/s10194-017-0780-8CrossRefPubMedPubMedCentral

27.

Russo A, Santangelo G, Tessitore A, Silvestro M, Trojsi F, De Mase A, Garramone F, Trojano L, Tedeschi G (2019) Coping Strategies in Migraine without Aura: A Cross-Sectional Study. Behav Neurol 2019:5808610. https://doi.org/10.1155/2019/5808610

28.

Smith M, Nakamoto M, Crocker J, Tiffany Morden F, Liu K, Ma E, Chong A, Van N, Vajjala V, Carrazana E, Viereck J, Liow K (2021) Early impact of the COVID-19 pandemic on outpatient migraine care in Hawaii: Results of a quality improvement survey. Headache 61(1):149–156. https://doi.org/10.1111/head.14030CrossRefPubMed

29.

Ong JJY, Bharatendu C, Goh Y, Tang JZY, Sooi KWX, Tan YL, Tan BYQ, Teoh HL, Ong ST, Allen DM, Sharma VK (2020) Headaches Associated With Personal Protective Equipment - A Cross-Sectional Study Among Frontline Healthcare Workers During COVID-19. Headache 60(5):864–877. https://doi.org/10.1111/head.13811CrossRefPubMed

30.

Rapisarda L, Trimboli M, Fortunato F, De Martino A, Marsico O, Demonte G, Augimeri A, Labate A, Gambardella A (2021) Facemask headache: a new nosographic entity among healthcare providers in COVID-19 era. Neurol Sci. https://doi.org/10.1007/s10072-021-05075-8CrossRefPubMedPubMedCentral

Title: Impact of the COVID-19 pandemic on migraine in Japan: a multicentre cross-sectional study
Authors: Keisuke Suzuki
Takao Takeshima
Hisaka Igarashi
Noboru Imai
Daisuke Danno
Toshimasa Yamamoto
Eiichiro Nagata
Yasuo Haruyama
Takashi Mitsufuji
Shiho Suzuki
Yasuo Ito
Mamoru Shibata
Hisanori Kowa
Shoji Kikui
Tomohiko Shiina
Madoka Okamura
Muneto Tatsumoto
Koichi Hirata
Publication date: 01-12-2021
Publisher: Springer Milan
Keywords: Migraine
COVID-19
Aura
Headache
Anxiety
Published in: The Journal of Headache and Pain / Issue 1/2021
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-021-01263-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Impact of the COVID-19 pandemic on migraine in Japan: a multicentre cross-sectional study

Abstract

Objectives

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Association between response to triptans and response to erenumab: real-life data

CGRP induces migraine-like symptoms in mice during both the active and inactive phases

Altered amygdala effective connectivity in migraine without aura: evidence from resting‐state fMRI with Granger causality analysis

Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies

Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study